Immunotherapy plus chemotherapy before surgery shows promise against tough stomach cancers

NCT ID NCT07699939

First seen Jul 13, 2026 · Last updated Jul 24, 2026 · Updated 4 times

Summary

This trial investigates whether adding the immunotherapy drug serplulimab (HLX10) to standard chemotherapy (S-1 and oxaliplatin) before and after surgery can improve outcomes for people with locally advanced, PD-L1-positive stomach or gastroesophageal junction cancer. Participants are randomly assigned to receive either the combination or chemotherapy alone, and the main goal is to see if the combination leads to a higher rate of complete tumor disappearance at the time of surgery. The study is double-blind and placebo-controlled to ensure reliable results.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
serplulimab (HLX10) plus S-1 and oxaliplatin
What this could lead to
If successful, this combination could become a new standard treatment to shrink tumors before surgery and reduce the chance of cancer returning in patients with advanced gastric cancer.
What could go wrong
This is a phase 2 trial with 136 participants, so results are preliminary. Adding immunotherapy to chemotherapy may increase side effects, and the benefit may not be confirmed in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ajou University Hospital

    NOT_YET_RECRUITING

    Suwon, Gyeonggi-do, South Korea

  • Asan Medical Center

    NOT_YET_RECRUITING

    Songpa-dong, South Korea

  • Cancer Institute Hospital of JFCR

    NOT_YET_RECRUITING

    Koto-Ku, Tokyo, Japan

    Contact Phone: •••-•••-••••

  • Chiba Cancer Center

    RECRUITING

    Chiba, Chiba, 260-8717, Japan

    Contact Phone: •••-•••-••••

  • Gifu University Hospital

    NOT_YET_RECRUITING

    Gifu, Gifu, Japan

    Contact Phone: •••-•••-••••

  • Gunma University Hospital

    NOT_YET_RECRUITING

    Maebashi, Gunma, Japan

    Contact Phone: •••-•••-••••

  • Hiroshima University Hospital

    NOT_YET_RECRUITING

    Hiroshima, Hiroshima, Japan

    Contact Phone: •••-•••-••••

  • Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center

    NOT_YET_RECRUITING

    Yokohama, Kanagawa, Japan

    Contact Phone: •••-•••-••••

  • Kyushu Cancer Center

    NOT_YET_RECRUITING

    Fukuoka, Fukuoka, 811-1395, Japan

    Contact Phone: •••-•••-••••

  • National Cancer Center Hospital

    RECRUITING

    Chuo Ku, Tokyo, 104-0045, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Cancer Center Korea

    NOT_YET_RECRUITING

    Goyang-si, Gyeonggi-do, South Korea

  • Osaka International Cancer Institute

    NOT_YET_RECRUITING

    Osaka, Osaka, Japan

    Contact

  • Osaka Medical and Pharmaceutical University Hospital

    NOT_YET_RECRUITING

    Takatsuki, Osaka, Japan

    Contact Phone: •••-•••-••••

  • Saitama Medical University International Medical Center

    NOT_YET_RECRUITING

    Hidaka, Saitama, Japan

    Contact Phone: •••-•••-••••

  • Saitama Prefectural Cancer Center

    NOT_YET_RECRUITING

    Ina, Kitaadachi-gun, Japan

    Contact Phone: •••-•••-••••

  • Seoul St. Mary's Hospital

    NOT_YET_RECRUITING

    Seocho, Seoul, South Korea

  • Shizuoka Cancer Center

    NOT_YET_RECRUITING

    Nagaizumi-chō, Sunto-gun, Japan

    Contact Phone: •••-•••-••••

  • St. Marianna University Hospital

    RECRUITING

    Kawasaki, Kanagawa, Japan

    Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.